Respiratory Syncytial Virus Vaccine, Recombinant, Pre-Fusion F Protein 3, Older Adult
Prevention of RSV-confirmed lower respiratory tract disease (LRTD) in adults aged ≥75 years, First Nations adults aged 60-74 years, and adults aged 60-74 years with medical conditions associated with increased risk of severe RSV disease.
Access path
- Mar 2026Recommended
vs no vaccine
- PBS listing · Restricted
Cost-effectiveness
ICER values are redacted (commercially sensitive). The PBAC considered revised cost inputs reasonable at the December 2025 intracycle meeting for the two previously recommended populations; however, no specific ICER figures are stated in the public text.
The PBAC considered that the revised cost inputs for the economic evaluation were reasonable, and that the vaccine was cost effective at the price proposed for adults aged at least 75 YOA and First Nations adults 60-74 YOA. PBAC · 2026
Decision context
PopulationThree populations: (1) adults aged ≥75 years; (2) First Nations adults aged 60-74 years; (3) adults aged 60-74 years with at least one medical condition associated with increased risk of severe RSV disease (as defined in the Australian Immunisation Handbook).
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2026 | Recommended | no vaccine | — | RCT |